To further understand the differential response to ibrutinib between the UM-CLL and M-CLL, we investigated the activities of downstream kinases in the BCR signaling pathways, including PLCγ2, ERK, and AKT. This evidence concerns the gene PLCG2 and B-cell chronic lymphocytic leukemia.